Compare FCBC & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCBC | WVE |
|---|---|---|
| Founded | 1874 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 928.3M | 744.8M |
| IPO Year | 1996 | 2015 |
| Metric | FCBC | WVE |
|---|---|---|
| Price | $47.79 | $3.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $17.68 |
| AVG Volume (30 Days) | 74.0K | ★ 3.0M |
| Earning Date | 10-27-2026 | 11-09-2026 |
| Dividend Yield | ★ 4.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | $17.48 | $19.15 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.35 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $31.21 | $3.04 |
| 52 Week High | $50.17 | $21.73 |
| Indicator | FCBC | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 53.73 | 19.93 |
| Support Level | $47.54 | N/A |
| Resistance Level | $49.57 | $4.07 |
| Average True Range (ATR) | 0.98 | 0.19 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 59.01 | 5.35 |
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.